(19)
(11)EP 2 906 578 B8

(12)CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15)Correction information:
Corrected version no 1 (W1 B1)

(48)Corrigendum issued on:
26.06.2019 Bulletin 2019/26

(45)Mention of the grant of the patent:
08.05.2019 Bulletin 2019/19

(21)Application number: 13846070.4

(22)Date of filing:  11.10.2013
(51)International Patent Classification (IPC): 
C07H 15/26(2006.01)
A61K 31/70(2006.01)
C07D 311/30(2006.01)
A61P 9/00(2006.01)
(86)International application number:
PCT/AU2013/001175
(87)International publication number:
WO 2014/056038 (17.04.2014 Gazette  2014/16)

(54)

NOVEL FLAVONOID COMPOUNDS AND USES THEREOF

NEUARTIGE FLAVONOIDVERBINDUNGEN UND VERWENDUNGEN DAVON

NOUVEAUX COMPOSÉS FLAVONOÏDES ET LEURS UTILISATIONS


(84)Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)Priority: 11.10.2012 AU 2012904444

(43)Date of publication of application:
19.08.2015 Bulletin 2015/34

(73)Proprietor: ARMARON BIO PTY LTD
Kew VIC 3101 (AU)

(72)Inventor:
  • MCLACHLAN, Grant Andrew
    Box Hill South, Victoria 3128 (AU)

(74)Representative: Hoffmann Eitle 
Patent- und Rechtsanwälte PartmbB Arabellastraße 30
81925 München
81925 München (DE)


(56)References cited: : 
WO-A1-2006/094357
WO-A2-01/21608
WO-A1-2013/020184
WO-A2-2008/011538
  
  • CHENG XUE QIN ET AL: "Understanding the Cardioprotective Effects of Flavonols: Discovery of Relaxant Flavonols without Antioxidant Activity", JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, no. 6, 1 March 2008 (2008-03-01), pages 1874-1884, XP055248947, US ISSN: 0022-2623, DOI: 10.1021/jm070352h
  • GOHIL V.M ET AL.: 'Nutrient-sensitized screening for drugs that shift energymetabolism from mitochondrial respiration to glycolysis' NATURE BIOTECHNOLOGY vol. 28, no. 3, 2010, pages 249 - 257, XP008138302 & CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 4143-62-8, & CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 6889-80-1,
  • DATABASE CAS 08 March 2012 STN Database accession no. 1360535-03-0
  • DATABASE CAS 20 October 2010 STN Database accession no. 1246650-40-7
  • DATABASE CAS 24 January 2010 STN Database accession no. 1203316-35-1
  • DATABASE CAS 27 April 2008 STN Database accession no. 017495-84-9
  • DATABASE CAS 30 October 2007 STN Database accession no. 951921-38-3
  • DATABASE CAS 15 February 2005 STN Database accession no. 831240-79-0
  • DATABASE CAS 25 January 2005 STN Database accession no. 819835-19-3
  • DATABASE CAS 25 January 2005 STN Database accession no. 819830-02-9
  • DATABASE CAS 10 September 2004 STN Database accession no. 742656-25-3
  • WU B E ET AL.: 'Evaluation of 3,3',4'-Trihydroxyflavone and 3,6,4'-Trihydroxyflavone (4'- O-Glucuronidation) as the in Vitro Functional Markers for Hepatic UGT1A1' MOLECULAR PHARMACEUTICS vol. 8, no. 6, 2011, pages 2379 - 2389, XP055245872 & CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 1345720-40-2, & CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 1345720-42-4, & CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 1345720-44-6,
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).